The biggest question going into the J.P. Morgan Healthcare Conference every year is which big company is going to announce a large acquisition. Amgen, Inc. CEO Robert Bradway’s answer on 11 January at this year’s meeting is that there are not many opportunities out there for larger transactions at a feasible price, but there is a lot of smaller firms with technology that can help the company boost its longer-term research and development goals, like Arrakis Therapeutics.
Amgen and Arrakis announced prior to Bradway’s J.P. Morgan presentation that the companies entered into a research collaboration for the...








